Biotech on The Soothsayer / page 2

Finland’s biotech sector is experiencing significant growth, with nine companies making headlines in the industry. Aplagon, DelSiTech, and Desentum are among the companies developing innovative treatments for various diseases, including thromboinflammatory diseases, chronic hepatitis B, and allergies. These companies have secured significant funding and are making progress in their clinical trials, indicating a promising future…

Candel Therapeutics and Cullinan Therapeutics are making significant strides in the development of new treatments for lung cancer. Candel’s viral immunotherapy, CAN-2409, has shown promising results in a phase 2a trial, achieving a prolonged median overall survival of 24.5 months in advanced NSCLC patients. Meanwhile, Cullinan’s EGFR ex20ins inhibitor, zipalertinib, has met its primary endpoint…

Nine promising small molecule drug discovery companies have raised funding in the last year, with Ascentage Pharma and 858 Therapeutics leading the charge in cancer treatment. Ascentage Pharma’s most advanced candidate, olverembatinib, has been cleared in China for certain patients with chronic myeloid leukemia and is in phase 3 trials for multiple cancer indications. Meanwhile,…

Montreal, the largest city in Canada’s Quebec province, has emerged as a leading biotech hub, rivaling Vancouver and Toronto. The city’s life sciences sector has experienced significant growth, driven by advancements in pharmaceuticals, digital health, and artificial intelligence. This article highlights nine promising biotech companies in Montreal, including Ability Biotherapeutics, Congruence Therapeutics, and Cura Therapeutics,…

Alnylam Pharmaceuticals has received FDA approval for its RNAi therapy, Qfitlia, for the treatment of hemophilia A or B. This breakthrough marks the sixth Alnylam-discovered medicine using its RNAi therapeutic platform to be approved. Additionally, Be Biopharma is developing engineered B cell medicines, including BE-101, which has entered clinical trials for hemophilia B. These advancements…

The UK biotech scene is experiencing a significant surge in funding, with a $700 million influx in the third quarter of 2023. This has led to the development of innovative technologies, with several companies spinning out of the nation’s most prestigious universities. The biotech hubs in the UK, including the famous ‘golden triangle’ of Oxford,…

Seven biotech companies are working on clinical drug candidates to treat hepatitis B, a serious liver infection affecting 254 million people worldwide. Companies like Assembly Biosciences and Barinthus Biotherapeutics are using innovative technologies such as capsid assembly modulators and antigen-specific immunotherapy to develop new treatments. These breakthroughs offer hope for a cure and improved management…

The biotech industry has made significant progress in treating and preventing HIV, but a true cure remains elusive. Recent developments in gene editing and synthetic antibodies have sparked hope for a breakthrough. Companies like AELIX Therapeutics and Excision BioTherapeutics are working on innovative therapies, including CRISPR-based treatments and therapeutic vaccines. These advancements could reshape the…

Altos Labs, a leading anti-aging biotech company, has made significant strides in the field of cellular rejuvenation. With a $3 billion investment and a team of renowned scientists, the company has successfully extended the lifespan of mice using targeted partial reprogramming. This breakthrough has sparked considerable investment in startups seeking to rejuvenate humans, and experts…

Artificial intelligence (AI) is transforming the biotech industry, enabling companies to accelerate the drug discovery process while reducing costs. The COVID-19 pandemic highlighted the potential of AI in finding treatments and vaccines with greater speed and precision. This article explores 12 AI drug discovery companies making significant strides in their technology, including Anima Biotech and…